MIRA Pharmaceuticals, Inc. (MIRA)
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
- Ticker
- MIRA
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Market cap
- $26.89M
- 52-week range
- $0.51 - $1.69
Valuation
- Share price
- $0.59 (close of Nov 18, 2026)
- P/E (TTM)
- -1.85x
- Price to book
- 3.93x
- Price to free cash flow
- -5.56x
- Enterprise value
- $19.92M
- Book value per share
- $0.16
Price performance
| Period | Change |
|---|---|
| 1 day | -7.81% |
| 5 days | -4.84% |
| 1 month | -6.35% |
| 3 months | -22.37% |
| 6 months | -39.80% |
| Year to date | -60.93% |
| 1 year | -58.16% |
| 3 years | -82.23% |
| All time | -92.05% |
Short interest
- As of
- Oct 30, 2026
- Short % of float
- 0.97%
- Shares short
- 282.32K
- Days to cover
- 1.44
- Change since prior report
- -19.27%
- Source
- FINRA consolidated short interest
Profitability and growth
- Return on equity
- -100.49%
- Return on invested capital
- -101.44%*
- Return on assets
- -94.13%
- Return on capital employed
- -101.44%*
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -18.00%
- Current ratio
- 16.97x
- Net debt to EBITDA
- 0.73x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- EBITDA
- -$10.44M
- Net income
- -$10.44M
- Research and development
- $1.72M
Income statement by year
| Period end | Net income |
|---|---|
| 2025-12-31 | -$10.44M |
| 2024-12-31 | -$7.85M |
| 2023-12-31 | -$11.98M |
| 2022-12-31 | -$7.06M |
Margins and returns by year
| Period end | Return on equity | Return on capital |
|---|---|---|
| 2025-12-31 | -100.49% | -101.44%* |
| 2023-12-31 | -273.92% | -194.69%* |
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash and debt by year
| Period end | Cash |
|---|---|
| 2025-12-31 | $11.03M |
| 2024-12-31 | $2.83M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | -$4.66M | $6.31M |
| 2024-12-31 | -$5.56M | $1.92M |
| 2023-12-31 | -$4.53M | $2.55M |
| 2022-12-31 | -$5.60M | $1.30M |
| 2021-12-31 | -$1.38M | - |
| 2020-12-31 | -$67.99K | - |
Investor relations
Next earnings report
- Next confirmed report
- Nov 19, 2026
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-11-12 | Sep 2026 | - |
| 2026-08-12 | Jun 2026 | - |
| 2026-05-14 | Mar 2026 | - |
| 2025-11-13 | Sep 2025 | - |
| 2025-08-14 | Jun 2025 | -$0.11 |
| 2025-05-14 | Mar 2025 | -$0.15 |
| 2025-03-28 | Dec 2024 | -$0.29 |
| 2024-11-12 | Sep 2024 | -$0.18 |
Filings and sources
- Company website
- mirapharmaceuticals.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Eli Lilly & Co (LLY) · Johnson & Johnson (JNJ) · AbbVie Inc. (ABBV) · Merck & Co., Inc. (MRK) · Novartis AG (NVS) · AstraZeneca plc (AZN) · Amgen Inc (AMGN) · Gilead Sciences, Inc. (GILD)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades